PPD sells biomarkers biz to Caprion

By Gareth Macdonald

- Last updated on GMT

Related tags Revenue Stock market

US CRO PPD has sold its biomarker discovery sciences unit to Caprion Proteomics, bucking the trend that has seen many of its sector rivals invest in this part of the contract research market.

Caprion, which has provided biomarker discovery and validation services to the drug industry since 2002, said the acquisition had strengthened its market position and broadened its client portfolio and revenue base.

CEO Martin LeBlanc stressed that a key motivation for the deal was “the growing biomarker needs​” of Caprion’s clients, which is an observation also cited by Covance​, Icon​, Quintiles​ and WuXi AppTec​ who have all recently invested in biomarkers.

The prevailing wisdom is that demand for biomarker analysis in discovery has increased in line with efforts to reduce attrition rates for early-stage because the approach means that only the most promising candidates are selected.

All of which makes sale of the Menlo Park, California biomarker unit seem like a counterintuitive move for PPD, particularly at a time when, biomarkers aside, demand for early-stage development is yet to fully recover after the economic downturn.

However, the move does make sense in the context of PPD business as a whole, given that discovery sciences is the smallest part of its business, generating just $1.1m of the $426.6m it reported in its most recently reported quarter.

It also fits with plans to spin off its compound partnering division, which is on track to take place in the first half of the year, and acquisition of Chinese CRO Exel PharmaStudies​ as a way of strengthening its Phase II-IV operations.

Guidance disappoints

Business strategy was also a key topic for PPD when it issued its 2010 guidance last week. The CRO predicted that net revenue for the year will be in the $1.3bn to $1.43bn range, on earning per share of between $1.00 and $1.12.

CEO David Grange stressed “strengthening our business models, establishing innovative partnerships and enhancing our global capacity” as key goals for the year but did not go into any details.

He also said that: “We have entered 2010 with clear objectives to restore growth in our business and to create long-term value for our shareholders​.”

Despite Grange’s optimism, PPD’s share price was down 6.5 per cent in after hours trading the day it made the announcement as investors responded to the lower-than-expected earnings guidance.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us

Products

View more

Webinars